960 TT-816, a novel small molecule immune checkpoint inhibitor targeting cannabinoid CB2receptor, stimulates innate and adaptive immunity for cancer therapy

Peidong Fan, Elfatih Elzein, Lina YaoRegular 2022 · DOI

TL;DR

TT-816 is a novel, oral small-molecule drug that acts as a selective antagonist for the cannabinoid $CB_2$ receptor, effectively functioning as a new type of immune checkpoint inhibitor. By blocking $CB_2R$, the drug simultaneously inhibits tumor cell growth and reactivates both innate and adaptive immune responses, and it is currently being evaluated in Phase 1 clinical trials.

What Problem Does This Paper Address?

The "endocannabinoid system" is well-known for its role in the central nervous system, but it is also a potent regulator of the immune system. Specifically, the G-protein coupled cannabinoid $CB_2$ receptor ($CB_2R$) is frequently overexpressed in various tumor microenvironments. High levels of $CB_2R$ and its natural ligands are often associated with more aggressive cancers and a suppressed immune response.

While existing immune checkpoint inhibitors (like those targeting PD-1 or CTLA-4) have revolutionized oncology, many patients do not respond to them. There is a critical need for new targets that can "flip the switch" in the tumor microenvironment from an immunosuppressive state to an active, anti-tumor state. This paper introduces TT-816 as a candidate to fill that gap by targeting the $CB_2$ pathway.

Methods

The researchers employed a suite of pharmacological and cell-based assays to characterize TT-816:

  • Receptor Binding & Selectivity: They used CHO-K1 cells engineered to express human $CB_2R$ to measure how tightly TT-816 binds (IC50) and compared it to the $CB_1$ receptor to ensure selectivity.
  • Functional Signaling: To confirm TT-816 acts as an antagonist (a blocker), they measured $GTP\gamma S$ binding (an indicator of G-protein activation) and cAMP production (a downstream signaling molecule).
  • Immune Activation Assays:
    • Innate Immunity: They pretreated Natural Killer (NK) cells with TT-816 and co-cultured them with K562 cancer cells to measure "killing" efficiency.
  • Adaptive Immunity: They performed Mixed Lymphocyte Reactions (MLR) by co-culturing T cells with dendritic cells to see if the drug could stimulate T cell proliferation and cytokine production.
  • Direct Tumor Effects: The drug was tested against human breast, colorectal, and lung cancer cell lines to observe direct growth inhibition.

Datasets

As a preclinical pharmacology study, this paper does not use large-scale computational datasets. Instead, it relies on:

  • Engineered Cell Lines: CHO-K1 cells expressing human $CB_2R$.
  • Cancer Cell Lines: K562 (leukemia), as well as various breast, colorectal, and lung cancer lines.
  • Primary Human Cells: CD4+ T cells and monocyte-derived dendritic cells sourced from donors for the immune assays.

Key Insights and Ideas

  • High Selectivity is Crucial: One of the biggest hurdles in cannabinoid research is avoiding the $CB_1$ receptor, which is responsible for the psychoactive effects of cannabis. TT-816 shows >380-fold selectivity for $CB_2$ over $CB_1$, suggesting a cleaner safety profile.
  • Antagonism vs. Agonism: While some research explores activating cannabinoid receptors for pain or inflammation, this study highlights that blocking (antagonizing) $CB_2R$ is the key to unleashing the immune system against cancer.
  • A Multi-Pronged Attack: TT-816 doesn't just do one thing. It appears to work through three distinct channels:
  • Directly inhibiting the growth of cancer cells.
  • Boosting Innate Immunity by making NK cells more effective killers.
  • Boosting Adaptive Immunity by helping dendritic cells "prime" T cells more effectively, leading to increased $IFN-\gamma$ and T cell proliferation.

Key Results

  • Potency: TT-816 bound to human $CB_2R$ with an IC50 of 26.2 nM.
  • Immune Markers: Treatment significantly increased the expression of critical immune-activation markers, including CD86, HLA-DR, IL-12, and TNF-$\alpha$ in dendritic cells.
  • Functional Impact: The drug concentration-dependently enhanced the ability of NK cells to kill cancer cells and increased the production of Interferon-gamma ($IFN-\gamma$), a key cytokine for anti-tumor immunity.
  • Broad Efficacy: Growth inhibition was observed across multiple major cancer types, including breast, lung, and colorectal models.

Limitations and Future Work

The abstract provides a high-level summary of preclinical success, but several questions remain:

  • In Vivo Complexity: While the cell culture results are promising, the complex "tug-of-war" of a living tumor microenvironment is harder to replicate. The paper mentions preclinical data demonstrated antitumor activity, but specific animal model data (like tumor volume reduction over time) isn't detailed here.
  • Mechanism of Growth Inhibition: The exact molecular pathway by which $CB_2$ antagonism directly stops cancer cell division (e.g., cell cycle arrest vs. apoptosis) is not fully detailed.
  • Clinical Transition: The most significant "future work" is already underway: Phase 1 clinical trials. These will determine if the potency and selectivity seen in the lab translate to safety and efficacy in human patients with solid tumors.

Summary updated

Abstract

<h3>Background</h3> The endocannabinoid system is widely expressed in the human body, including the innate and adaptive immune system, where endocannabinoids, Δ9-tetrahydrocannabinol and synthetic ligands regulate immune response. The effects of endocannabinoids on immune regulation are primarily mediated by G-protein coupled cannabinoid CB<sub>2</sub> receptors (CB<sub>2</sub>R) via several mechanisms, including development, migration, proliferation and effector functions. The upregulated expression of CB<sub>2</sub>R and elevated levels of endocannabinoids have been observed in a variety of tumor microenvironments and are associated with the aggressiveness of cancer. <h3>Methods</h3> Membranes prepared from CHO-K1 cells stably expressing human CB<sub>2</sub>R were used for receptor binding assays in the presence of TT-816 and [3H]CP-55,940, and for GTPγS binding assay in the presence of TT-816, 10 μM GDP and 0.3 nM [35S]GTPγS. cAMP assay was performed by incubating the CHO-K-1 cells for 30 min with TT-816, 25 μM forskolin and 12 nM CP-55,940, or with TT-816 and 5 μM forskolin. NK cell function was determined by co-culturing TT-816 pretreated NK cells with K562 cancer cells for 24 hours. The mixed lymphocyte reaction assay was conducted by co-culturing human CD4+ T cells with monocyte-derived dendritic cells. Cell viability was measured by FACS and IFN-γ by MSD. <h3>Results</h3> TT-816 is a competitive and selective CB<sub>2</sub>R antagonist. It bound to human CB<sub>2</sub>R with an IC50 26.2 nM, showing greater than 380-fold selectivity over cannabinoid CB<sub>1</sub> receptors. The ability of TT-816 to inhibit the constitutive activity of CB<sub>2</sub>R was characterized in both GTPγS and cAMP assays. TT-816 concentration-dependently inhibited the basal GTPγS binding response, antagonized CB<sub>2</sub>R agonist-mediated cAMP production and enhanced the forskolin response on basal cAMP level. Consistent with its inhibition of CB<sub>2</sub>R function, TT-816 inhibited the growth of human breast, colorectal and lung cancer cells. In addition, TT-816 concentration-dependently enhanced the functions of NK cells, dendritic cells and T cells. It increased NK cell killing of the human cancer cells and IFN-γ production, significantly stimulated the expression of CD86, HLA-DR, IL-12 and TNF-a in monocyte-derived dendritic cells, and enhanced CD4+ T cell proliferation and IFN-γ production in a mixed lymphocyte reaction assay. <h3>Conclusions</h3> TT-816 is a novel, oral small molecule immune checkpoint inhibitor that selectively blocks CB<sub>2</sub>R on cancer cells and immune cells. Preclinical data have demonstrated that it stimulates antitumor innate and adaptive immune response and inhibits cancer cell proliferation. TT-816 is currently undergoing phase 1 clinical trials for the treatment of a broad range of solid tumors.
BibTeX
@inproceedings{fan2022tt,
  author = {Peidong Fan and Elfatih Elzein and Lina Yao},
  title = {{960 TT-816, a novel small molecule immune checkpoint inhibitor targeting cannabinoid CB<sub>2</sub>receptor, stimulates innate and adaptive immunity for cancer therapy}},
  booktitle = {Regular},
  year = {2022},
  doi = {10.1136/jitc-2022-sitc2022.0960},
}
Figure